Aarti Pharmalabs Ltd (AARTIPHARM) is currently trading at 872.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Aarti Pharmalabs manufactures APIs, pharmaceutical intermediates, HPAPIs, Xanthine derivatives, and provides end-to-end small-molecule CDMO/CMO services. Its seven manufacturing units, three R&D facilities, regulated-market approvals, and presence across more than 50 export countries support a diversified platform serving generic, innovator, biotech, beverage, pharmaceutical, and nutraceutical customers. The company delivered a sharp H1-FY27 recovery, with consolidated revenue increasing 42.5% year-on-year to INR 11,462 million, EBITDA rising 57.1% to INR 2,673 million, and PAT growing 121.6% to INR 1,476 million. This improvement occurred despite elevated raw-material costs and higher finance expenses, highlighting stronger operating leverage and product mix. Xanthine derivatives remain the company’s largest business, representing 50% of Q2-FY27 revenue and benefiting from a capacity increase to 9,600-plus MTPA. Aarti Pharmalabs expects global market share to rise from 15–20% to 20–25% as the expanded, non-Chinese-dependent platform ramps through FY27, strengthening its China-plus-one positioning. CDMO/CMO is becoming a meaningful growth engine: the company serves 23 customers across 59 active projects, including 39 commercial projects and 20 under development. CDMO sales rose from INR 32 crore in FY22 to INR 276 crore in FY26, while the company is expanding sales presence in the United States and Europe. The growth strategy is capital intensive and increasingly focused on complex chemistry. Aarti Pharmalabs is investing in Atali Block 2, new steroid capacity, and TIDES-related R&D covering peptides and oligonucleotides, while targeting 15–18% revenue and EBITDA CAGR over the next three to four years.

Over the past 52 weeks, Aarti Pharmalabs Ltd has traded between a low of ₹583.85 and a high of ₹1,001.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Aarti Pharmalabs Ltd has a market capitalization of approximately 8,411.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Aarti Pharmalabs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.77 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 8,411.01 Cr, Aarti Pharmalabs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Aarti Pharmalabs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Aarti Pharmalabs Ltd is 32.77. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Aarti Pharmalabs is scheduled to consider and approve its Q2 FY27 and half-year results on Wednesday, October 28, 2026.

It received an order dated August 29, 2026 from the Office of the Superintendent of Stamps, Gandhinagar, levying stamp duty and penalties totaling ₹59.50 crore (₹595 million).

The dataset lists a ₹2 final dividend for equity shares with an ex-date of 15 Sep 2026 and a record date of 15 Sep 2026.

In Q1 FY27, consolidated operational revenue was ₹535.8 crore and consolidated PAT was ₹76.1 crore. Standalone operational revenue was ₹534.6 crore and standalone PAT was ₹71.3 crore.